compounded glp-1 medications FDA says that the shortage is over Little Drugs - Agile Telehealth
Description
AZ paid $185m to Eccogene, with potential future payments of $1.8bn
95% CI 6.44 to 1.15
This might have hampered the incentive to investigate the potential effects of GLP1 receptor agonists as a treatment against AUD, as patients are already at a higher risk for developing pancreatitis or pancreatic cancer (National Institute for Health and Care Excellence, 2011)
Eliza Sun, Executive Director of the Board, Hansoh Pharma
